ENDOTAK LEAD SYSTEM
Boston Scientific · Decision date Sep 17, 2026
What did the FDA approve?
FDA records P910073/S193 as a supplement to PMA P910073, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Sep 17, 2026.
FDA approval order statement
approval for supplemental labeling for the ENDOTAK RELIANCE ePTFE family of defibrillator leads to align with a July 2025 Product Advisory.
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 17, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P910073/S193
- Regulatory pathway
- PMA supplement
- Applicant
- Boston Scientific
- Product code
- LWS
- Decision code
- APPR
- Decision date
- Sep 17, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implantable cardioverter defibrillator (non-CRT).
- Applicant
- Boston Scientific
- Product code
- LWS
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P910073. Subsequent supplements may change the device or its indications.
FDA decision timeline
P910073 · Original PMA
ENDOTAK LEAD SYSTEM
P910073/S193 received
Application receipt date recorded by FDA.
P910073/S193 · FDA decision
Special (Immediate Track)
Timeline entries are records held by MedtechLedger for P910073. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P910073
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ENDOTAK LEAD SYSTEMP910073 | Boston Scientific | PMA approval | Aug 26, 1993 | FDA |
Explore the linked device profile
Other records with product code LWS
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Nov 5, 2026 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Nov 4, 2026 | FDA | |
Cobalt MRI ICD, Cobalt XT MRI ICD, Crome MRI ICDP980016/S967 | Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 29, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 4100 Hamline Ave. N, St Paul, MN, 55112
Sources and methodology
- Original FDA record: P910073/S193
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


